NEW DELHI: Serum Institute of India and Bharat Biotech are expected to pursue late stage clinical trials of intranasal Covid-19 vaccines in the coming months once they receive regulatory approval, Union health minister Harsh Vardhan said on Sunday.
Vardhan said the late stage trial generally involves thousands of participants, sometimes 30,000 to 40,000.
Of the vaccines currently in Phase 3 trials, all are administered by injection, according to the World Health Organization (WHO).
On Saturday, India’s Dr Reddy’s Laboratories Ltd and the Russian Direct Investment Fund (RDIF) said they have received renewed approval to conduct late-stage clinical trials in India of the Russian COVID-19 vaccine.
India’s coronavirus infections rose by another 61,871 over the past 24 hours, data released on Sunday showed, although the health ministry said it is seeing a trend of steadily declining active cases.
The Indian Council of Medical Research (ICMR) said it will revisit its protocol for Covid-19 treatment after the WHO found some of the commonly used drugs, including remdesivir, had little or no impact on a patient’s chances of surviving.
Source:ToI
You may also like
-
Ayurveda and Diabetes Prevention: Lifestyle Lessons from Classical Principles
-
India Examines Regulatory Reforms to Allow Global Pharmaceutical Companies to Conduct First-in-Human Clinical Trials
-
CSIR-CCMB Scientists Identify New Potential Drug Targets Against Tuberculosis Bacterium
-
Ayurveda for Healthy Metabolism: Balancing Agni, Nutrition and Daily Living
-
India Records 38% Decline in TB Mortality, Achieves 94% Treatment Success Rate
